Chronic pulmonary aspergillosis – diagnosis and management in resource-limited setting

Professor Retno Wahyuningsih
Professor of Medical Mycology
Department of Parasitology, Faculty of Medicine
Universitas Indonesia and Universitas Kristen Indonesia
Jakarta, Indonesia
Chronic pulmonary aspergillosis (CPA) – diagnosis & management in resource-limited setting

Retno Wahyuningsih

Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia
Chronic Pulmonary Aspergillosis

• Long-term aspergillosis in the lung, a slowly progressive & destructive disease
• Caused by: A. *fumigatus* (>), A. *niger* & A. *flavus* (<)
• IDSA guideline:
  – Simple aspergilloma: cavity with a fungus ball inside
  – Chronic cavitary pulmonary aspergillosis (CCPA) – complex aspergilloma
  – chronic necrotizing pulmonary aspergillosis (CNPA)
• Untreated may develop fibrosis – worsening of the disease
## Diagnostic criteria for different management of chronic pulmonary aspergillosis (CPA)

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple aspergilloma</td>
<td>Single pulmonary cavity containing a fungal ball, with serological or microbiological evidence implicating Aspergillus spp. in a non-immunocompromised patient with minor or no symptoms and no radiological progression over at least 3 months of observation.</td>
</tr>
<tr>
<td>CCPA</td>
<td>One or more pulmonary cavities (with either a thin or thick wall) possibly containing one or more aspergillomas or irregular intraluminal material, with serological or microbiological evidence implicating Aspergillus spp. with significant pulmonary and/or systemic symptoms and overt radiological progression (new cavities, increasing pericavitary infiltrates or increasing fibrosis) over at least 3 months of observation.</td>
</tr>
<tr>
<td>CFPA</td>
<td>Severe fibrotic destruction of at least two lobes of lung complicating CCPA leading to a major loss of lung function. Severe fibrotic destruction of one lobe with a cavity is simply referred to as CCPA affecting that lobe. Usually the fibrosis is manifest as consolidation, but large cavities with surrounding fibrosis may be seen.</td>
</tr>
<tr>
<td>Aspergillus nodule</td>
<td>One or more nodules which may or may not cavitate are an unusual form of CPA. They may mimic tuberculosis, carcinoma of the lung, coccidioidomycosis and other diagnoses and can only be definitively diagnosed on histology. Tissue invasion is not demonstrated, although necrosis is frequent.</td>
</tr>
<tr>
<td>SAIA</td>
<td>Invasive aspergillosis, usually in mildly immunocompromised patients, occurring over 1–3 months, with variable radiological features including cavitation, nodules, progressive consolidation with “abscess formation”. Biopsy shows hyphae in invading lung tissue and microbiological investigations reflect those in invasive aspergillosis, notably positive Aspergillus galactomannan antigen in blood (or respiratory fluids).</td>
</tr>
</tbody>
</table>

Denning et al. EJR Express 2015
CPA: epidemiology

• affect > 3 million people worldwide,
• ~1.2 million have had tuberculosis.

(Denning – LIFE)
CPA: pathogenesis

• Underlying condition that accommodates cavity formation or causes tissue damaged
• A fertile site for the grow of *Aspergillus*
• *Aspergillus* destroys lung tissues by invasion, production of proteolytic enzymes, toxins and other metabolites that make things worse

Izumikawa et al. J Infect Chemother 2014
CPA: underlying condition

• Use of alcohol, tobacco abuse, suffer diabetes: deterioration in local or systemic defenses against infection
• Bronchopulmonary disease – presence of cavity:
  – active PTB/ residual PTB
  – bronchial dilatation,
  – sarcoidosis/COPD)
• Prolonged use of low-dose oral or inhaled corticosteroids
• Absence of or presence of very little vascular invasion

Camuset et al., Chest 2017; 131: 1435-41
### Table 2. Underlying conditions of CPA patients

<table>
<thead>
<tr>
<th>Respiratory conditions</th>
<th>CNPA (n=7)</th>
<th>Group A (n=5)</th>
<th>CCPA (n=8)</th>
<th>SA (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior tuberculosis</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Prior pneumonia</td>
<td>3</td>
<td>4</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Pneumothorax or bullae</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>COPD or emphysema</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Prior thoracic surgery</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Other respiratory conditions</td>
<td>2</td>
<td>4</td>
<td>9</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systemic conditions</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Steroid usage</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Other systemic conditions</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Smoking (&gt;20 y)</td>
<td>5</td>
<td>2</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Malnutrition (BMI &lt;18.5)</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

Izumikawa et al. J Infect Chemother 2014
Signs & symptoms

• Pulmonary disease that most of the time could not differ from other pulmonary infection

• Need other diagnostic information:
  – Imaging: cavity, nodule, etc
  – Mycology investigations: culture, serology (precipitin test)
### Symptoms of patients with chronic aspergillosis

<table>
<thead>
<tr>
<th></th>
<th>CNPA (n=7)</th>
<th>Group A (n=5)</th>
<th>CCPA (n=8)</th>
<th>SA (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex; male/female</strong></td>
<td>6/4</td>
<td>4/1</td>
<td>7/1</td>
<td>3/4</td>
</tr>
<tr>
<td><strong>Age; mean (range)</strong></td>
<td>59.1 (45-75)</td>
<td>67.0 (50-77)</td>
<td>69.7 (58-80)</td>
<td>56.6 (40-68)</td>
</tr>
<tr>
<td><strong>BMI; mean (range)</strong></td>
<td>18 (13-21)</td>
<td>17 (14-19)</td>
<td>20 (16-26)</td>
<td>21 (18-24)</td>
</tr>
</tbody>
</table>

#### Symptoms

- **Cough**: 5 5 7 4
- **Sputum**: 5 2 3 3
- **Hemoptysis**: 1 5 6 4
- **Dyspnea**: 3 1 2 0
- **Fever**: 4 2 0 0
- **Malaise**: 3 0 0 0
- **Weight loss**: 1 2 0 0

#### Duration; median (range)

- **CNPA**: 3 m (1 m-6 y)
- **Group A**: 24 m (17 m-6 y)
- **CCPA**: 29 m (6 m-5 y 4 m)
- **SA**: 24 m (6 m-4 y)

---

Table was modified from Izumikawa et al. J Infect Chemother 2014
CPA: Diagnosis

- Symptoms lasting > 3 months, usually are weight loss, fatigue, cough, haemoptysis & breathlessness
- CX-rays showing cavities ≥ 1 or nodules (early)
- Key diagnostic: precipitin test to detect antibody (IgG) anti Aspergillus) in serum/other body fluid
CPA: Diagnosis

• Laboratory investigation:
  – Sputum
    • Direct: branched hyphae
    • culture: positive rate ~ 25%
  – PCR: more sensitive, but many remains negative

• Biopsy:
  – Conventional mycology (direct & culture)
  – histopathology
CPA: treatment

• No codified treatment yet
• Bronchial artery embolization for hemoptysis
• Surgery: impairment of respiratory function or severity of comorbid does not allow surgery plus high morbidity & mortality.
• Antifungal:
  – Itraconazole
  – voriconazole

Glimp & Bayer Arch Intern Med 1983; 143:303–308;
Resource limited setting

• History: underlying condition, treatment

• Clinical presentation:
  – PTB sequelae or misdiagnosed with PTB or
  – Co-infection with PTB
  – Other underlying condition
Resource limited setting

- Diagnosis: usually the conventional (direct investigation & culture) mycology test are available
  - weakness sensitivity & specificity
  - Contamination? Colonization?
Resource limited setting: Treatment

• Voriconazole
• Itraconzole:
  – Widely used anti-fungal either for invasive infections such as aspergillosis as well as superficial infections
  – Emergence of resistant strains to itraconazole
  – Wide use for treatment of superficial & systemic mycoses
  – Use of azole derivative in agriculture
Patient with underlying condition & infection

Antibiotic

No response

Clinical information

Imaging

Lab. result: mycology, TB (neg)

response

Continue AB

AF treatment: itraconazole, (voriconazole)
Prognosis

• CPA is often diagnosed late leads to improper treatment
• Progresses toward worsening in line with pulmonary tissue destruction
• Mortality rate is ca. 15-30% in the first six months after diagnosis.
• What we can do is to halt the progressive lung tissue destruction
Chronic cavitary pulmonary aspergillosis

CASE REPORT
Case report: physical examination

A 60 year old lady with recurrent hemoptysis

looked ill and cachectic
loss weight during the last 10 years
1998: pulmonary TB, clinical signs, chest X ray, sputum acid fast bacilli (+)

Anti TB six month, sputum was cleared from acid fast bacilli

D/pulmonary TB

2003: sputum acid fast bacilli (+).

Category II of anti TB - 9 months, declared cured, no acid fast bacilli.

D/ relaps pulmonary TB

2007: cough & blood streak for the 1st time.

Acid fast bacilli negative.

One week AB, symptoms were disappeared.

Diagnosis: residual symptoms of TB.
History:

**February 2010**
profuse hemoptysis, admitted to the hospital.
chest CT scan - right lung: rough broncho-vascular pattern, bronchiectasis, fibrosis, cavities on top.
Acid fast bacilli (-)
Pulmonary lesion: residual process of former TB.
AB was given, clinical symptoms were disappeared.

**March 2011**
profuse hemoptysis, admitted to the hospital for one week, acid fast bacilli (-)
CXR was unchanged
Diagnosis: infected bronchiectasis, prev. TB and recurrent hemoptysis,
Discharged: cough almost everyday, blood streak (+/-).
AB and symptomatic treatment: no response
Work and family history

No other diseases and no significant family history.

Civil servant since a long period of time.

2007, her office was moved to an old, dump building because her previous office was being renovated.

3-4 months later: 1st hemoptysis.

Almost a year in the dump building, moved back to her newly renovated building office. None of her colleagues have such a complaint.
Lab investigation

May 2011:
sputum 3 days,
C. albicans,
Aspergillus antibody (+)

July 2011:
sputum 3 days,
A. niger,
Aspergillus antibody (+).

August 2011:
hemoptysis +
spt. A. fumigatus,
susceptible to itraconazole and voriconazole, SDD to amphotericine B.

September 2011 PCP was identified, but no treatment was given, the patient feel well and clinically looks good.
The result of both CXR of 2010 & 2011 are the same.
CT scan Augusts 2011

The result shows right lung destruction
Based on Chest CT scan and previous lab investigations, the diagnosis were:

- Chronic cavitary pulmonary aspergillosis (CCPA)
- Post TB
- Destroyed right lung
  - Bronchiectasis, athelectasis
  - Multiple bullae
  - Fungus ball
Itraconazole, 400 mg/day for 10 days, cont by 200 mg/day for one week. Eryhtromycin 250 mg/day as anti inflammatory agent for her bronchiectasis, with good response, patient feel much better.

Itraconazole was given because antibody against Aspergillus was positive, eventhough sputum investigations yield C. albicans.
A month later a sputum investigation (3X) was done. A. niger was isolated and antibody against Aspergillus remain +.

The patient feels much better.

400 mg itraconazole/day was added and clinically looks well.
August 2011: hemoptysis, *A. fumigatus* was isolated; susceptible to itracon & voricon, amphotericine B is SDD

**Chest CT scan:** right destroyed lung (bronchiectasis, athelectasis, multiple bullae with possibility of fungus balls).

**Treatment:** itraconazole 200 mg/day for 2 weeks
Acknowledgement

- Dept. of Parasitology Universitas Indonesia, Jakarta
  - Anna Rozaliyani
- Gatot Subroto Army Hospital, Jakarta
  - D. A. Kusmana
  - Y. Fajar
Thank you

MMTN Kuala Lumpur August 6, 2017

Early morning in Jayapura, Papua, Indonesia